Literature DB >> 22245539

Cytoprotective effect of nonsteroidal antiinflammatory drugs in rat brain slices subjected to reoxygenation after oxygen-glucose deprivation.

Juan Antonio López-Villodres1, José Pedro De La Cruz, Javier Muñoz-Marin, Ana Guerrero, José Julio Reyes, José Antonio González-Correa.   

Abstract

The aim of this study was to assess the possible neuroprotective effect of the main nonsteroidal antiinflammatory drugs (NSAIDs) in an experimental model of hypoxia-reoxygenation in rat brain slices. After reoxygenation the increase in lactate dehydrogenase (LDH) efflux was inhibited by nimesulide, celecoxib and meloxicam with an IC(50) in the 10(-6)M range, by flurbiprofen, ibuprofen and diclofenac in the 10(-5)M range, and by salicylic acid, indomethacin, acetylsalicylic acid and mefenamic acid the 10(-4)M range. The effect of other NSAIDs was seen with an IC(50) greater than 10(-3)M. A statistically significant linear correlation between the values of LDH efflux and prostaglandin E(2) was found for NSAIDs whose IC(50) of cytoprotection (LDH efflux) was below 10(-4)M. The concentration of interleukin 10 was increased with nimesulide, celecoxib, meloxicam, flurbiprofen, ibuprofen and diclofenac. Flurbiprofen and diclofenac significantly inhibited the production of lipid peroxides. The increase in brain nitrite levels was significantly reduced with celecoxib, flurbiprofen, diclofenac and salicylic acid. Concentrations of 3-nitrotyrosine were significantly reduced with celecoxib, flurbiprofen, ibuprofen, salicylic acid and ketorolac. In conclusion, NSAIDs with the greatest cytoprotective effect (nimesulide, celecoxib and meloxicam) may exert their effect mainly through the blockade of cyclooxygenase-2 (COX-2) activity. Other compounds with neuroprotective activity may complement their lower anti-COX-2 effect with a slight increase in interleukin 10 and reduced oxidative and nitrosative stress in our model of hypoxia-reoxygenation in rat brain slices.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245539     DOI: 10.1016/j.ejps.2012.01.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

Review 1.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

2.  Celecoxib Exerts a Therapeutic Effect Against Demyelination by Improving the Immune and Inflammatory Microenvironments.

Authors:  Peipei Cao; Hao Zhang; Huiling Meng; Yajia Cheng; Haiqi Xu; Siwen Zang; Zongjin Li; Jianlin Cui; Yuhao Li
Journal:  J Inflamm Res       Date:  2020-12-01

3.  R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice.

Authors:  Katja Schmitz; Natasja de Bruin; Philipp Bishay; Julia Männich; Annett Häussler; Christine Altmann; Nerea Ferreirós; Jörn Lötsch; Alfred Ultsch; Michael J Parnham; Gerd Geisslinger; Irmgard Tegeder
Journal:  EMBO Mol Med       Date:  2014-11       Impact factor: 12.137

4.  Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation.

Authors:  Vanessa Porrini; Ilenia Sarnico; Marina Benarese; Caterina Branca; Mariana Mota; Annamaria Lanzillotta; Arianna Bellucci; Edoardo Parrella; Lara Faggi; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.